

Biohit Oyj - Managers' Transactions - Siltala

Person subject to the notification requirement

Name: Päivi Siltala

Position: Chief Executive Officer

Issuer: Biohit Oyj

LEI: 74370089ATTSNBXJVT29

Notification type: INITIAL NOTIFICATION

Reference number: 9324/4/6

Transaction date: 2022-01-14

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT
INSTRUMENT

Instrument name: I 2021A

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Linked to stock option programme

Transaction details

(1): Volume: 20000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 20000 Volume weighted average price: 0 EUR

Transaction date: 2022-01-14

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT
INSTRUMENT

Instrument name: I 2021B

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Linked to stock option programme

Transaction details

(1): Volume: 20000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 20000 Volume weighted average price: 0 EUR

Transaction date: 2022-01-14

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT
INSTRUMENT

Instrument name: I 2021C

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 20000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 20000 Volume weighted average price: 0 EUR

Transaction date: 2022-01-14

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Instrument name: I 2021D

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 20000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 20000 Volume weighted average price: 0 EUR

Transaction date: 2022-01-14

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Instrument name: I 2021E

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 20000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 20000 Volume weighted average price: 0 EUR

Transaction date: 2022-01-14

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Instrument name: II 2021A

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 25000 Volume weighted average price: 0 EUR

Transaction date: 2022-01-14

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Instrument name: II 2021B

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 25000 Volume weighted average price: 0 EUR

Transaction date: 2022-01-14

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Instrument name: II 2021C

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 25000 Volume weighted average price: 0 EUR

Transaction date: 2022-01-14

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Instrument name: II 2021D

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 25000 Volume weighted average price: 0 EUR

CEO Päivi Siltala, Biohit Oyj

tel. +358 9 773 861

investor.relations@biohit.fi

www.biohithealthcare.com

Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's mission is "Innovating for Health" – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com